Drug intelligence / Profile preview

Code STD

Development stage: Unknown
Lead developer: Johnson & Johnson
Modality: Small Molecules
Administration: Oral

Overview

Code STD is an experimental 2 mg single-dose oral nicotine replacement therapy product developed by McNeil AB. It is being evaluated for bioequivalence against Nicorette Microtab in healthy smokers. As a nicotine product, its mechanism of action involves nicotine replacement to aid in smoking cessation.

Other names: experimental nicotine product coded "STD"

Targets

Nicotinic Acetylcholine Receptor

Beyond the preview

Go deeper on Code STD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Code STD.

Explore the full profile